![]() |
CZECH MEDICAL ASSOCIATION J. Ev. PURKYNĚ |
Journals - Article | |
![]() |
![]() ![]() ![]() ![]() ![]() ![]() ![]() |
Česky / Czech version | Vnitř. Lék., 50, 2004, No. 11, p. 818 - 824 |
Rosiglitazon in Treatment of Type II Diabetes Mellitus - Experience
of Diabetologists in the Czech Republic. Part I: Compensation of Diabetes, Sugar Metabolism Perušičová J.1, Haas T.2 1Diabetologické centrum, III. interní klinika 1. lékařské fakulty UK a VFN, Praha, přednostaprof. MUDr. Štěpán Svačina, DrSc. 2Ústav biofyziky 1. lékařské fakulty UK, Praha, přednosta doc. Ing. Miroslav Šprnda, CSc. |
|
Summary: Thiazolidindione derivates (glitazones) make a very promising group of peroral antidiabetic
drugs. They are represented by rosiglitazon which is available on our market to type II diabetics.
As far as sugar metabolism is concerned, rosiglitazon can reduce glycaemia and insulin level both
when fasting and postprandially. Goal: The goal of the authors' work was to gain their own
experience with rosiglitazon treatment in type II diabetics in the Czech Republic. Sample: The
monitored sample consisted of 388 patients with insufficiently compensated type II diabetes when
treated by sulphonylurea compounds or metformine. Methods: 95 diabetologists from diabetology
medical offices started a 6-month-long treatment with rosiglitazon (Avandia) dose of 4 mg a day as
stated in European recommendations. In order to assess changes in sugar metabolism (compensation
of diabetes) glycaemia and C peptide were monitored when fasting and postpradially and
HbA1c was monitored in 2-month-long intervals. Results: Weight, waist-hip ratio (WHR) and Cpeptide
levels remained unchanged. Statistically significant (p < 0.0001) was a HbA1c decrease
over 6 month from 9.61 % to 8.48 %. Fasting glycaemia decreased by 2.49 and postprandial glycaemia
by 2.71 mmol/l. No significant side effects were identified. Conclusion: Rosiglitazon administration
combined with administration of sulphonylurea compounds or metformine significantly
improved compensation of diabetes compared to initial therapy.
|
|
Order this issue
|
BACK TO CONTENTS | ||
| HOME PAGE | CODE PAGE | CZECH VERSION | |
© 1998 - 2008 CZECH MEDICAL ASSOCIATION J. E. PURKYNĚ |
Created by: NT Servis, s.r.o., hosted by P.E.S. consulting, s.r.o. |
WEBMASTER |